ESMA issues opinions on product intervention measures by Sweden, France and the United Kingdom
The European Securities and Markets Authority (ESMA) yesterday issued three opinions on product intervention measures taken by the National Competent Authorities (NCAs) of Sweden, France and the United Kingdom. ESMA’s opinion finds that the proposed measures are justified and proportionate and that it is necessary for NCAs of other Member States to take product intervention measures that are at least as stringent as ESMA’s measures.
ESMA has issued opinions on national product intervention measures from:
- The Financial Conduct Authority of the United Kingdom (FCA) – Opinion on the proposed product intervention measures relating to contracts for differences;
- The Autorité des Marchés Financiers of France (AMF) – Opinion on the proposed product intervention measures relating to contracts for differences;
- The Finansinspektionen of Sweden (FI) – Opinion on the proposed product intervention measures relating to contracts for differences.
ESMA’s opinion on the UK proposed measures also concludes that the measures are justified and proportionate and qualifies this conclusion in relation to:
(i) the FCA’s proposal not to apply the national restrictions to CFD-like option providers authorised in other Member States other than through a UK branch or tied agent in respect of the sale or distribution of those products to UK retail clients; and
(ii) the FCA’s proposal to apply a 30:1 leverage limit for CFDs referencing certain government bonds, instead of the 5:1 leverage limit in ESMA’s measures.
In accordance with Article 43(3) of MiFIR if a competent authority takes actions contrary to an opinion adopted by ESMA, it shall immediately publish on its website a notice fully explaining its reasons for so doing.
NCAs may take product intervention measures in accordance with Article 42 of Regulation (EU) No 600/2014. At least one month before a measure is intended to take effect, an NCA must notify all other NCAs and ESMA of the details of its proposed measure and the related evidence, unless there is an exceptional case where it is necessary to take urgent action.
In accordance with Article 43 of Regulation (EU) No 600/2014, ESMA performs a facilitation and coordination role in relation to such product intervention measures taken by NCAs. After receiving notification from an NCA of its proposed measure, ESMA must adopt an opinion on whether the proposed measure is justified and proportionate. If ESMA considers that the taking of a measure by other NCAs is necessary, it must state this in its opinion.
The opinions that ESMA previously issued on proposed national product intervention measures are published on its website.
ESMA Opinion Under Article 43(2) MIFIR (SE_CFD)
ESMA Opinion Under Article 43(2) MIFIR (FR_CFD)
ESMA Opinion Under Article 43(2) MIFIR (UK_CFD)
Latest News from
EC opens investigation into possible anti-competitive conduct of Amazon18/07/2019 15:25:00
The EC has opened a formal antitrust investigation to assess whether Amazon's use of sensitive data from independent retailers who sell on its marketplace is in breach of EU competition rules.
Turkish drilling activities in the Eastern Mediterranean16/07/2019 15:25:00
The Council adopted the following conclusions on the Turkish drilling activities in the Eastern Mediterranean.
Four new substances added to the Candidate List16/07/2019 13:43:00
The Candidate List of substances of very high concern (SVHCs) for authorisation now contains 201 substances.
Imports of hormone-free beef: EU-US agreement confirmed16/07/2019 11:43:00
The Council has adopted a decision on the signing of an agreement between the EU and the US on the allocation to the US of a share in the TRQ for high quality beef regarding the importation of beef from animals not treated with certain growth-promoting hormones.
EIOPA consults on the harmonisation of national insurance guarantee schemes15/07/2019 12:32:00
Tthe European Insurance and Occupational Pension Authority (EIOPA) has launched a consultation on its Advice on the harmonisation of national insurance guarantee schemes across the Member States of the European Union.
EU-U.S. trade talks: milestone reached in mutual recognition on pharmaceuticals12/07/2019 15:25:00
The EU and the USA have delivered on a significant element of the Joint Statement agreed by Presidents Juncker and Trump in July 2018. The positive transatlantic trade agenda established in the Joint Statement includes a commitment from both sides to reduce barriers and increase trade in a range of sectors, including pharmaceuticals.
Airbnb cooperates with EC and EU consumer authorities improving the way it presents offers12/07/2019 13:25:00
The EC has announced that, as a result of negotiations with Airbnb, the platform has improved and fully clarified the way it presents accommodation offers to consumers, which is now in line with the standards set in EU consumer law.
European Institute of Innovation and Technology: EC proposes strategy for 2021-202712/07/2019 11:33:00
The EC has proposed an update of the legal base of the European Institute of Innovation and Technology (EIT) as well as its new Strategic Innovation Agenda for 2021-2027.
EC approves GlaxoSmithKline's acquisition of Pfizer's Consumer Health Business with conditions11/07/2019 15:25:00
The EC has approved, under the EU Merger Regulation, the acquisition of Pfizer's Consumer Health Business by GlaxoSmithKline. The decision is conditional upon the global divestment of Pfizer's topical pain management business carried out under the ThermaCare brand.